Literature DB >> 10623705

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

J E Harris1, L Ryan, H C Hoover, R K Stuart, M M Oken, A B Benson, E Mansour, D G Haller, J Manola, M G Hanna.   

Abstract

PURPOSE: A randomized phase III clinical trial of adjuvant active specific immunotherapy (ASI) with an autologous tumor cell-bacillus Calmette-Guérin (BCG) vaccine was conducted to determine whether surgical resection plus ASI was more beneficial than resection alone in stage II and III colon cancer patients. PATIENTS AND METHODS: Patients (n = 412) with colon cancer (297 with stage II disease, 115 with stage III disease) were randomly allocated to an observation arm or to a treatment arm in which they received three weekly intradermal vaccine injections of 10(7) irradiated autologous tumor cells beginning approximately 4 weeks after surgery. The first two weekly injections also contained 10(7) BCG organisms. Patients were observed for determination of time to recurrence and disease-free and overall survival.
RESULTS: This was a negative study in that after a 7.6-year median follow-up period, there were no statistically significant differences in clinical outcomes between the treatment arms. However, there were disease-free survival (P =.078) and overall survival (P =.12) trends in favor of ASI when treatment compliance was evaluated, ie, patients who received the intended treatment had a delayed cutaneous hypersensitivity (DCH) response to the third vaccination (induration >/=5 mm). Also, the magnitude of the DCH response correlated with improved prognosis. The 5-year survival proportion was 84.6% for those with indurations greater than 10 mm, compared with 45.0% for those with indurations less than 5 mm.
CONCLUSIONS: When all randomized patients were evaluated, no significant clinical benefit was seen with ASI in surgically resected colon cancer patients with stage II or III colon cancer. However, there was an indication that treatment compliance with effective immunization results in disease-free and overall survival benefits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623705     DOI: 10.1200/JCO.2000.18.1.148

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  56 in total

1.  New developments in autologous tumor cell vaccination therapy for renal cell carcinoma.

Authors:  A J van den Eertwegh ; H M Pinedo
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

3.  PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer.

Authors:  David C Qian; Xiangjun Xiao; Jinyoung Byun; Arief A Suriawinata; Stephanie C Her; Christopher I Amos; Richard J Barth
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

Review 4.  Use of tumour-responsive T cells as cancer treatment.

Authors:  Mary L Disis; Helga Bernhard; Elizabeth M Jaffee
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

Review 5.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 6.  Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review.

Authors:  Benqiang Rao; Minyan Han; Lei Wang; Xiaoyan Gao; Jun Huang; Meijin Huang; Huanliang Liu; Jianping Wang
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

Review 7.  The emerging role of immunotherapy in colorectal cancer.

Authors:  David Lynch; Adrian Murphy
Journal:  Ann Transl Med       Date:  2016-08

Review 8.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer.

Authors:  Michael G Hanna; Jason Howard; Jan Vermorken
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Adjuvant therapy of colon cancer: current status and future developments.

Authors:  Michael A Morse
Journal:  Clin Colon Rectal Surg       Date:  2005-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.